Given a document, find the main entity about whom the author is writing. Write the full name if mentioned in the text. Note that URLs in the text have been replaced with [Link].

Example Input: One of the reasons  Jimmy Vesey  didnât sign with  his  hometown Bruins when the Harvard product was a college free agent in 2016 was because  he  wanted to get out of  his  comfort zone.  He  sure looks comfortable playing against them.
 Vesey  scored twice in a 29-second span in the first period in the Rangersâ 4-2 home win Wednesday night against Boston  the Blueshirtsâ fifth straight win as they continue to distance themselves from their rough start to the year.
For Buchnevichâs fellow sophomore Vesey  Wednesday represented some progress in that he remained a contributor until the final horn. In three of the previous five games   Vesey  had either had limited third-period ice time or been benched altogether for the third.
 Jimmy Vesey  celebrates  his  first of two goals scored. (Bruce Bennett/Getty Images)
âMaybe he wasnât finishing on a lot  but  Jimmy  was working hard and  like you saw (Wednesday) early on  before he scored the goals  he made a couple real strong plays along the wall in our end that permitted us to get the puck out â Vigneault said. âSo thereâs more than just finishing.â
Example Output: Jimmy Vesey

Example Input: Ever since early 2016 , when the Republican Party began to fussily resettle itself behind Donald Trump , Mitt Romney has been an intermittent oppositional figure , distinct from his party in both point of view and style . 
The conservative movement has grown smirking , clannish , quarrelsome ; Romney has been formal , chiding , and pained . 
After Trump won the election , that November , Romney met with Trump in the hope of securing for himself the position of Secretary of State . 
Yet this summer , after a white-supremacist rally in Charlottesville turned deadly , Romney professed deeper anxieties . 
For half a century , Romney and his family have existed close to the center of the Republican Party . 
Now -- just six years removed from being his party 's Presidential nominee , but with no distinct Romneyist camp in Washington and no obvious constituency to summon -- it is n't obvious that Romney fits in at all . 
Last week , the Utah senator Orrin Hatch announced that he would be retiring at the end of his term this year , and immediately Romney 's allies suggested that he would run for the seat ; the common wisdom was that his election would be all but assured . 
-LRB- Romney , a man of many residences , built his political career in Massachusetts , but he went to college in Utah , and helped to save the Salt Lake City Olympics from ruin in 2002 ; he is the most recognizable Mormon in the world , and he would be running in a state whose Republican Party is defined by its relationship to the L.D.S. Church . -RRB- 
Romney 's candidacy is still unannounced , and its most important position -- what line the candidate takes on the President -- is not yet obvious . 
"This thing is still developing ," one of Romney 's longtime advisers told me last week . 
But already the most romantic vision of Romney -- that he might arrive in Washington as the de-facto leader of an anti-Trump faction -- seems unlikely . 
"I 've heard some relatively simplistic assessments that he is going to be the voice of the Never Trump movement ," a senior adviser to Romney 's Presidential campaign said last week . 
Romney is a very pragmatic politician , too . 
Romney himself has made no sign of wanting to be part of such a faction , even if it existed . 
One of his advisers reminded me last week that Romney took the idea of being Trump 's Secretary of State seriously , and believed that Trump 's interest in him was entirely sincere . 
And , a month after his appalled reaction to Charlottesville , Romney tweeted praise for Trump 's speech before the U.N. General Assembly . 
Romney 's potential for tragedy and heroism both spring from the same source : the depth of his feeling for a version of America that may exist only in his mind , a place where the trees in Michigan are exactly the right height . 
Romney 's return to Utah has some elements of a homecoming ; it is also , more simply , a move to accommodating political terrain . 
Utah is a conservative state whose politics are moving toward Romney , rather than away . 
Modern Utah , the place of the salvaged Salt Lake Olympics , exists in the Romney image .
Example Output: Mitt Romney

Example Input: The drug  called  Kymriah   is a highly personalized cancer treatment called CAR T-cell therapy (CAR is short for chimeric antigen receptor).
The FDA approved  Kymriah  to treat pediatric acute lymphoblastic leukemia in people up to age 25.
The one-time treatment isn't cheap: Novartis  which makes  Kymriah   on Wednesday said the price would be $475 000  which is lower than many expected. Only about 600 people a year could get this treatment  based on Wednesday's approval. Even so  the approval has industry experts and cancer doctors excited.
How  Kymriah  works
 Kymriah  isn't your run-of-the-mill pill â or even a biologic drug  like insulin â that can be mass produced. Since the therapy is made from a person's own immune system  the process can take about three weeks.
While that's a one-time process  it's not the end of the road. About half of the patients in a Kymriah study got cytokine-release syndrome  a response to the reprogrammed cells running loose in the body. It can cause high fevers and flu-like symptoms  and it can be life-threatening. If they get it  patients need to be admitted to intensive-care units  which can bring additional costs. (The FDA on Wednesday expanded the approval of Actemra  a rheumatoid-arthritis drug that can also treat cytokine-release syndrome.)
In a trial of 63 patients treated with Kymriah  83% were in remission after three months  and 64% were still in remission after a year.
Kymriah is the first CAR-T cell therapy to get approved  and several more are in the works. Kite Pharma  Juno Therapeutics  and Bluebird Bio are among a growing group of biotech companies working with CAR-T. Kite  which was recently acquired by Gilead Sciences  is expected to hear back from the FDA about its treatment for aggressive B-cell non-Hodgkin lymphoma by November.
"We're at the very beginning of what's going to be a big new field of medicine " said  David Epstein  who helped license Kymriah from the University of Pennsylvania while at Novartis .
 Epstein  left Novartis in 2016 as CEO of its pharmaceuticals divisions.  He 's now the executive chairman of Rubius Therapeutics  a biotech firm that's also working with cell therapy to develop treatments like  Kymriah  that don't have to be as personalized. The hope is that one day doctors will be able to prescribe a cell therapy and use it that same day instead of waiting weeks to get it back.
 Epstein  said  he  envisioned cell therapies having much shorter life cycles than traditional drugs. Instead of getting a better  updated therapy for a disease every decade or so  we might begin to see second-generation cell therapies in a few years.
Those updates could increase the number of patients that cell therapies can treat. The 600 or so people a year eligible for  Kymriah  now could become tens of thousands  but  it  would require some major changes   Epstein  said.
For one  the treatments would have to treat more types of cancer than the one  Kymriah  was approved for on Wednesday.
And to affect more people  the cell therapies would need to go beyond blood cancers. Right now  that's where most of the big successes have come from  but that could one day include solid tumors and maybe even autoimmune diseases like Type 1 diabetes   Epstein  said.
Example Output:
Kymriah